Evaluation of serum interleukin‐1 receptor antagonist levels in major depressive disorder: A case‐control study. Issue 4 (29th March 2023)

• Record Type: Journal Article
• Authors: Nahar, Zabun; Monisha, Shahrin Tasnim; Qusar, MMA Shalahuddin; Islam, Md. Rabiul
• Is Part Of: Health science reports. Volume 6:Issue 4(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2023-03-29
• Subjects: case‐control study -- cytokines -- depressive disorder -- interleukin‐1 receptor antagonist protein -- neuroinflammation; 610
• DOI: 10.1002/hsr2.1175
• Languages: English
• ISSNs: 2398-8835

Abstract

Abstract: Background and Aims: Major depressive disorder (MDD) is characterized by the occurrence of one or more depressive episodes lasting a minimum of 2 weeks and is marked by a persistently low mood and a lack of enjoyment in daily activities. The diagnosis of MDD is not possible by a well‐established laboratory test or biomarker. A wide range of potential biomarkers for depression have been proposed by many studies, but none of them has adequately described the correlation between the biomarkers and depression. The purpose of this study was to evaluate serum interleukin‐1 receptor antagonist (IL‐1RA) levels as an early depression risk factor. Methods: The present case‐control study included 88 participants. Among them, 44 MDD patients enrolled from the psychiatry department of a public hospital in Dhaka, Bangladesh, and 44 age‐ and sex‐matched healthy controls (HCs) from various sites in Dhaka city. A qualified psychiatrist evaluated the cases and HCs based on the fifth edition of the diagnostic and statistical manual of mental disorders (DSM‐5). The Hamilton depression (Ham‐D) rating scale was employed to evaluate the intensity of depression. An enzyme‐linked immunosorbent assay kit (Boster Bio, USA) was used to determine serum IL‐1RA concentrations. Results: We observed no marked alteration in the serum concentration of IL‐1RA in MDD patients in comparison to HCs (292.81 ± 24.81 and 288 ± 24.87 pg/mL; p > 0.05). Among MDD patients, we found no noteworthy association between the severity of depression and serum IL‐1RA levels. Conclusion: The findings of the present study imply that IL‐1RA may not be identified as a promising biomarker for risk assessment of depression. However, its neuroprotective role may be taken into consideration for the understanding of pathophysiology of MDD.